Trial reportAesthetic surgery journal2026
Mid- to Long-term Outcomes Following Primary Augmentation With B-Lite Lightweight Breast Implants: A Prospective Multicenter Postmarketing Clinical Follow-up Study.
Trial report in Aesthetic surgery journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundLightweight breast implants (B-Lite) integrate air-filled microspheres into silicone gel to reduce implant weight by up to 30% while maintaining volume and mechanical properties. Long-term prospective data in primary augmentation remain limited.
objectivesTo evaluate clinical performance, safety, satisfaction, and quality of life (QoL) outcomes following primary augmentation with B-Lite implants.
methodsThis multicenter, prospective, single-arm manufacturer-sponsored postmarketing clinical follow-up (PMCF) study enrolled genetically female patients (18-60 years) undergoing bilateral primary breast augmentation. Implants (round or anatomical; POLYsmoooth, POLYtxt, MESMO, or Microthane; 200-755 cc) were placed through inframammary incisions using a standardized technique. The primary endpoint was ≥1 bra-cup increase at 12 months; secondary endpoints included QoL (Body Esteem, Rosenberg, shortened Tennessee, RAND SF-36), satisfaction, and adverse events (AEs) such as capsular contracture (Baker III-IV), rupture, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), and reoperation.
resultsIn all, 101 patients (mean age 32.7 ± 8.0 years; BMI 20.9 ± 1.8) underwent augmentation. At 12 months, ≥1-cup increase occurred in 92% (95% CI, 84%-97%). No Baker III/IV contracture, rupture, or BIA-ALCL occurred. The most frequent AE was transient sensory change (8.9%); others were infrequent and mainly procedure related. Kaplan-Meier reoperation risk was 6.9% at 1 year and 9.9% at 5 years. Patient satisfaction averaged 98.6% with 0% regret; surgeons were satisfied or very satisfied at 97% to 100%. QoL showed durable gains in Body Esteem-sexual attractiveness and Rosenberg; SF-36 composites remained stable.
conclusionsLightweight B-Lite implants showed high effectiveness, very high satisfaction, and a favorable safety profile through 3 to 5 years. LEVEL OF EVIDENCE: 2: For image description, please refer to the figure legend and surrounding text.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.